Skip to main content

Table 2 Risk factors for reinfection: analysis adjusted for EIR only. Data from 2130 individuals in the AS-AQ trial arms and 2090 in the AL trial arms were analyzed using accelerated failure-time analysis. Regression coefficients are the ratio of time to reinfection, such that a coefficient > 1 indicates a longer time to reinfection. All results are adjusted for log EIR. Site-level random effects were included unless otherwise indicated. Models assume a lognormal time to reinfection

From: The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data

Covariate (unit)Analysis adjusted for EIR only
NCoefficient [ratio of reinfection times] (95% CI)p value
Loge EIR (annual bites per person)42200.79 (0.74, 0.85)< 0.001
AL20901 (ref) 
 AS-AQ (overall)21301.09 (1.05, 1.13)< 0.001
 AS-AQ (20% 86Y)*19341.37 (1.28, 1.47)< 0.001
 AS-AQ (80% 86Y)*19340.89 (0.84, 0.94)< 0.001
Age (polynomial, years, > 20 grouped together)4213 < 0.001
 age 0.94 (0.90, 0.98) 
 (age)2 1.01 (1.00, 1.02) 
 (age)3 0.9998 (0.9994, 1.0001) 
Male gender38610.98 (0.95, 1.02)0.438
Anemic (hb < 10 g/dl)37470.98 (0.93, 1.02)0.277
Enlarged spleen (yes/no)13901.00 (0.87, 1.15)0.999
Presence of fever (> 37.5 °C)42200.97 (0.93, 1.01)0.146
Underweight (weight-for-age Z score < −2)31930.98 (0.93, 1.04)0.613
AQ dose (per 10 mg per kg increase) (AS-AQ arms only)18391.00 (0.95, 1.06)0.880
Lumefantrine dose (per 10 mg per kg increase) (AL arms only)18501.02 (1.00, 1.04)0.015
AS-AQ formulation
 FDC15211 (ref) 
 Loose NFDC3730.83 (0.59, 1.18)0.295
 Coblistered NFDC (AS-AQ arms only)2331.06 (0.68, 1.64)0.803
pfmdr1 86Y prevalence (per 10% increase)
 AL arm18911.03 (0.99, 1.07)0.091
 AS-AQ arm19340.96 (0.94, 0.98)< 0.001
pfcrt 76T prevalence (per 10% increase)
 AL arm19641.03 (1.00, 1.07)0.037
 AS-AQ arm20010.97 (0.95, 1.00)0.052
  1. *In a model including log10 EIR, drug, pfmdr1 86Y prevalence (per 10% increase) and interaction between drug and pfmdr1 86Y prevalence
  2. Site-level random effects not included because many sites did not measure this covariate
  3. p value interaction between drug and pfmdr1 86Y vs N86 prevalence < 0.001, p value interaction between drug and pfcrt 76T vs K76 prevalence < 0.001